Functional influenza virus like particles (VLPs)
The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
1. A vaccine comprising an influenza VLP and a pharmaceutically acceptable carrier or excipient,
wherein the VLP comprises influenza M1, HA and NA proteins,
wherein the M1 protein is from an avian influenza virus,
wherein the M1 protein is from a different strain of influenza virus than the influenza HA protein and the influenza NA protein; and
wherein the vaccine induces substantial immunity to influenza virus infection in a human susceptible to influenza.
2. The vaccine of claim 1 , wherein said the HA and/or NA exhibit hemagglutinin activity and/or neuraminidase activity, respectfully.
3. The vaccine of claim 1 , wherein the influenza VLP comprises seasonal influenza virus HA and NA proteins.
4. The vaccine of claim 3 , wherein the seasonal influenza virus is a type A influenza virus.
5. The vaccine of claim 3 , wherein the seasonal influenza virus is a type B influenza virus.
6. The vaccine of claim 1 , wherein the influenza VLP comprises avian influenza HA and NA proteins.
7. The vaccine of claim 6 , wherein the avian influenza virus HA and NA proteins are an H5 protein and an N1 protein, respectively.
8. The vaccine of claim 6 , wherein the avian influenza virus HA and NA proteins are an H9 protein and an N2 protein, respectively.
9. The vaccine of claim 1 , wherein the influenza VLP is formulated with an adjuvant.
10. The vaccine of claim 9 , wherein the adjuvant comprises paucilamellar non-phospholipid vesicles.
11. The vaccine of claim 1 , wherein the vaccine further comprises a second VLP, wherein the second VLP comprises a HA protein and an NA protein from a different influenza strain than the HA protein and NA protein of the first VLP.
12. The vaccine of claim 1 , wherein the VLP consists essentially of influenza M1, HA and NA proteins.
13. The vaccine of claim 1 , wherein the VLP consists of influenza M1, HA and NA proteins.
14. The vaccine of claim 1 , wherein the M1 protein is derived from A/Indonesia/5/05.
15. A method of formulating a vaccine that induces substantial immunity to influenza virus infection to an animal susceptible to influenza, comprising adding an effective dose of an influenza VLP to a pharmaceutically acceptable carrier or excipient,
wherein the VLP comprises influenza M1, HA and NA proteins,
wherein the vaccine induces substantial immunity to influenza virus infection to the animal,
wherein the M1 protein is from an avian influenza virus; and
wherein the M1 protein is from a different strain of influenza virus than the influenza HA protein and the influenza NA protein.
16. The method of claim 15 wherein the VLP consists essentially of influenza M1, HA and NA proteins.
17. The method of claim 15 , wherein the VLP consists of influenza M1, HA and NA proteins.
18. The method of claim 15 , wherein the influenza VLP has been treated to inactivate baculovirus.
19. The method of claim 18 , wherein the inactivation treatment comprises incubating a sample comprising VLPs in about a 0.2% of β-propyl lactone (BPL) for about 3 hours at about 25° C.
20. A virus like particle (VLP) comprising influenza M1, HA and NA proteins, wherein the HA protein is derived from an H5 subtype influenza virus, wherein the NA protein is derived from an N1 subtype influenza virus, wherein the M1 protein is from an avian influenza virus, and wherein the M1 protein is from a different strain of influenza virus than the influenza HA protein and the influenza NA protein.
21. The VLP of claim 20 , wherein the HA protein or the NA protein are from a H5N1 Glade 1 influenza virus.
22. The VLP of claim 20 , wherein the HA protein and the NA protein are from a H5N1 Glade 2 influenza virus.
23. The VLP of claim 22 , wherein the HA and NA proteins comprise SEQ ID NOS: 43 and 46, respectively.
24. The VLP of claim 22 , wherein the HA and NA proteins comprise SEQ ID NOS: 50 and 54, respectively.
25. The VLP of claim 20 , wherein the HA and NA are from an influenza virus which was isolated from an infected animal.
26. The VLP of claim 22 , wherein the infected animal is a human.
27. The VLP of claim 20 , wherein the VLP is expressed from a eukaryotic cell comprising one or more nucleic acids encoding influenza HA and NA proteins and an influenza M 1 protein under conditions that permit the formation of VLPs.
28. The VLP of claim 27 , wherein the eukaryotic cell is selected from the group consisting of yeast, insect, amphibian, avian and mammalian cells.
29. The VLP of claim 28 , wherein the eukaryotic cell is an insect cell.
30. The VLP of claim 29 , wherein the insect cell is an Sf9 cell.
31. The VLP of claim 20 , wherein the VLP elicits neutralizing antibodies in a human or animal that are protective against influenza infection when administered to the human or animal.
32. An immunogenic composition comprising an effective dose of a VLP of claim 20 .
33. The composition of claim 32 , wherein the composition comprises an adjuvant.
34. A vaccine comprising an effective dose of a VLP of claim 20 .
35. The vaccine of claim 34 , wherein the vaccine comprises at least a second VLP which comprises HA and NA from different influenza strains.
36. The vaccine of claim 34 , wherein the vaccine comprises an adjuvant.